The European Parliament has called on the European Union's member states and the European Commission to tackle cardiovascular disease (CVD), the region's biggest killer. However, Members of the European Parliament focused on prevention strategies, public awareness campaigns and the promotion of healthy lifestyles over treatment, including drugs.
However, a European free-market think-tank, the Stockholm Network, repeated a call to action to address what it termed "the growing burden of high cholesterol." Last year, the group published a report calling for European governments to give greater priority to cholesterol lowering which, the SN argues, involves the promotion of statins (Marketletter April 10, 2006).
Crisis unresolved while drugs rationed
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze